Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)
Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%
Immunocore operating margin
Operating margin is operating income as a percentage of revenue.
Immunocore's operating margin for the twelve months ending Sep 30, 2026 was -6.8%. For fiscal 2025 it was -11.3%, against -22.7% the year before. The highest annual figure on record is -11.3% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -11.3% | +11.4 |
| FY2024 | Dec 31, 2024 | -22.7% | +1.2 |
| FY2023 | Dec 31, 2023 | -23.9% | +5.7 |
| FY2022 | Dec 31, 2022 | -29.7% | +448.9 |
| FY2021 | Dec 31, 2021 | -478.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -13.3% | −6.4 |
| Q2 FY2026 | Jun 30, 2026 | -2.6% | +12.6 |
| Q1 FY2026 | Mar 31, 2026 | 6.8% | +10.7 |
| Q4 FY2025 | Dec 31, 2025 | -18.8% | +4.3 |
| Q3 FY2025 | Sep 30, 2025 | -6.9% | +3.7 |
| Q2 FY2025 | Jun 30, 2025 | -15.2% | +6.1 |
| Q1 FY2025 | Mar 31, 2025 | -3.9% | +33.7 |
| Q4 FY2024 | Dec 31, 2024 | -23.1% | +1.2 |
| Q3 FY2024 | Sep 30, 2024 | -10.6% | +11.2 |
| Q2 FY2024 | Jun 30, 2024 | -21.2% | +1.8 |
| Q1 FY2024 | Mar 31, 2024 | -37.6% | −10.7 |
| Q4 FY2023 | Dec 31, 2023 | -24.3% | – |
| Q3 FY2023 | Sep 30, 2023 | -21.8% | – |
| Q2 FY2023 | Jun 30, 2023 | -23.0% | – |
| Q1 FY2023 | Mar 31, 2023 | -26.9% | – |
See a number that looks wrong?